Intranasal absorption of oxymorphone.
The nasal bioavailability of oxymorphone HCI was determined. Rats were surgically prepared to isolate the nasal cavity, into which a solution of oxymorphone was administered. A reference group of rats was administered oxymorphone HCl intravenously. Plasma oxymorphone concentrations were determined by HPLC. Nasal absorption was rapid, nasal bioavailability was 43%, and the iv and nasal elimination profiles were similar. Oxymorphone HCI appears to have the solubility, potency, and absorption properties required for efficient nasal delivery, which is an alternative to injections.
Hussain
M A
MA
The DuPont Merck Pharmaceutical Company, Pharmaceutical R&D, Wilmington, DE 19880-0400, USA.
Aungst
B J
BJ
D000281:Administration, Intranasal; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D000818:Animals; D019540:Area Under Curve; D001682:Biological Availability; D008297:Male; D009297:Nasal Mucosa / Q000378:metabolism*; D010111:Oxymorphone / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D051381:Rats; D011917:Rats, Inbred Lew
D000701:Analgesics, Opioid; D010111:Oxymorphone